SOURCE: AlphaRx Inc.

March 31, 2005 08:00 ET

AlphaRx to Present at JM Dutton Associates' West Coast "Recognizing Opportunity 2005" Conference in San Francisco

Live Webcast on Tuesday, April 5, 2005

MARKHAM, ON -- (MARKET WIRE) -- March 31, 2005 -- AlphaRx Inc. (OTC BB: ALRX), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, announced today that the Company's President, Michael Lee, will make a presentation at JM Dutton Associates' West Coast "Recognizing Opportunity 2005" Conference at the Four Seasons Hotel in San Francisco, California. Mr. Lee will deliver his presentation on Tuesday, April 5, 2005 at 8.30 a.m. Pacific Standard Time.

Investors may access a live webcast of the presentation at http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ALRX&item_id=1040065. The presentation will be archived for 90 days.

About AlphaRx Inc. (www.AlphaRx.com)

AlphaRx is an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs that are insoluble or poorly soluble in water or have yet to be administrable to the human body with an acceptable delivery method.

The Company is focusing on the clinical development of Indaflex™, a topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation intended for use in the treatment of symptoms of arthritis. Arthritis is the most common chronic condition in North America and afflicts an estimated 10% of the world's population. Indaflex's active ingredient, Indomethacin, has long-standing and proven clinical treatment records. With AlphaRx's enhanced proprietary delivery system, the Company believes its clinical effectiveness will be significantly enhanced compared to other topical preparations. Topical Indaflex delivery, the Company hopes, may circumvent the significant GI side effects found with orally ingested NSAIDs.

Forward-Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

Contact Information